|
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ |
CRºÎ¼ SSU ¾÷¹« Á¤±ÔÁ÷¿ø ä¿ë°ø°í
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
SSU |
1³â¡è |
»ó½Ãä¿ë |
02.23 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK global PS] SP / ERA / PL ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
12.02 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
ERºÎ¼ ÆÀÀå / ERA °æ·Â/ PL/ A.PL ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
1³â¡è |
ä¿ë½Ã |
10.05 |
|
|
Çѱ¹Organon |
Çѱ¹Organon Market Access ´ã´çÀÚ ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
01.15 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
MSD Clinical research associate(CRA)´Ù¼ö ¸ðÁý Áß
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
11.06 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
BDºÎ¼ BD Manager ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
1³â¡è |
ä¿ë½Ã |
08.03 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
CMºÎ¼ CM Manager °æ·Â ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
1³â¡è |
ä¿ë½Ã |
11.27 |
|
|
Çѱ¹¿¥¿¡½ºµð ÁÖ½Äȸ»ç |
[Çѱ¹MSD] MSL-ID/Vaccine
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
08.13 |
|
|
Çѱ¹¿¥¿¡½ºµð ÁÖ½Äȸ»ç |
[Çѱ¹MSDµ¿¹°¾àÇ°]-Technical Marketing Manager-¹Ý·Áµ¿¹°,
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
08.13 |
|
|
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ |
ÀÎÇã°¡»ç¾÷ºÎ ÀÇ·á±â±â»ç¾÷ÆÀ ½ÅÀÔ/°æ·Â ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
2³â¡è |
»ó½Ãä¿ë |
01.03 |
|
|
½Å¶óÁ¨(ÁÖ) |
Clinical DeliveryÆÀ¿ø(CDA) ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
12.11 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
(Sr.)CRA ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
07.24 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Oncology MSL 2¸í ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
10.31 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
[Çѱ¹MSD]Business practice officer(Compliance officer)
¼¿ï Áß±¸, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
2³â¡è |
ä¿ë½Ã |
05.10 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD CRA ´Ù¼ö ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.04 |
|